Dr Stephen James Hatch, MD | |
10228 Dupont Circle Dr E, Fort Wayne, IN 46825-1611 | |
(260) 490-2525 | |
(260) 490-7254 |
Full Name | Dr Stephen James Hatch |
---|---|
Gender | Male |
Speciality | Nurse Anesthetist, Certified Registered |
Location | 10228 Dupont Circle Dr E, Fort Wayne, Indiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1508839689 | NPI | - | NPPES |
20005080R | Medicaid | IN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208VP0014X | Pain Medicine - Interventional Pain Medicine | 01042223A (Indiana) | Primary |
367500000X | Nurse Anesthetist, Certified Registered | 01042223A (Indiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Stephen James Hatch, MD 10228 Dupont Circle Dr E, Fort Wayne, IN 46825-1611 Ph: (260) 490-2525 | Dr Stephen James Hatch, MD 10228 Dupont Circle Dr E, Fort Wayne, IN 46825-1611 Ph: (260) 490-2525 |
News Archive
Swiss researchers examining exposure pathways for a common chemical used in plastic containers and linings of cans find infants have the highest estimated levels of Bisphenol A (BPA), with exposures falling with rising age. While estimated levels are well below the Tolerable Daily Intake (TDI) set by European authorities, the findings are important in that BPA is thought to impact human development and is classified as an endocrine disrupting chemical, potentially putting developing infants at risk, as well as fetuses if pregnant mothers are exposed.
Fewer physicians are accepting Medicaid beneficiaries as new patients, in part because they say that reimbursements are too low and because of "administrative hassles," according to a study from the Center for Studying Health System Change, the AP/Long Island Newsday reports.
Fear and fear extinction learning are adaptive processes caused by molecular changes in specific brain circuits, and they're perturbed in conditions such as anxiety and post-traumatic stress disorder.
Vertex Pharmaceuticals Incorporated today announced that the Therapeutic Goods Administration of Australia has approved KALYDECO (ivacaftor) for people with cystic fibrosis ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator gene.
› Verified 2 days ago